By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


Haemophilia prophylactic licensed

A prophylactic agent has been granted a license for haemophilia A patients with inhibitors.

Factor VIII Inhibitor Bypassing Activity (FEIBA) reduces a patient’s risk of spontaneous bleeds, minimising long-term complications, according to manufacturer Baxter. It is the first bypassing agent to be granted a prophylaxis indication for this group of patients.

Kate Khair, nurse consultant in haemophilia at Great Ormond Street Hospital in London, said: ‘Treating patients with inhibitors with FEIBA prophylaxis has a profound effect on the everyday life of a patient.’

Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!